What is claimed:

1. A pharmaceutical composition comprising:
a water soluble matrix comprising an effective amount of a pharmaceutically active agent and an absorption enhancer having an HLB of about 8 to about 16; wherein the pharmaceutically active agent is selected from the group consisting of diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol.

2. The pharmaceutical composition of claim 1 wherein the pharmaceutical composition dissolves in the oral cavity in about 0.25 minutes to about 15 minutes.

3. The pharmaceutical composition of claim 1 or claim 2 wherein the diethylstilbestrol is present in an amount of from about 0.1 mg to about 5 mg .

4. The pharmaceutical composition of any one of claims 1 to 3 wherein the pharmaceutical active agent is an agent for the treatment prostate or breast cancer in a patient and is present in an amount which is effective for treating prostate or breast cancer.

5. The pharmaceutical composition any one of claims 1 to 4 wherein said matrix contains an absorption enhancer or a combination of absorption enhancers in a total amount of from about 0.1% by weight to about 20% by weight by weight of the matrix.

6. The pharmaceutical composition of any one of claims 1 to 5 wherein the absorption enhancer is one or more sucrose fatty acid esters having a combined HLB of about 8 to about 16.

7. The pharmaceutical composition of claim 6 wherein the sucrose fatty acid esters are sucrose fatty acid esters having a monomer content of from about 20 percent to about 80 percent.

8. The pharmaceutical composition of claim 6 or claim 7 wherein said sucrose fatty acid ester is a C12 to C20 saturated fatty acid ester of sucrose.

9. The pharmaceutical composition of claim 6 or claim 7 wherein the sucrose fatty acid esters are selected from the group consisting of sucrose stearate, sucrose palmitate, sucrose laurate, sucrose behenate, sucrose oleate and sucrose erucate.

10. The pharmaceutical composition of any one of claims 6 to 9 wherein said sucrose fatty acid ester is a sucrose stearate.

11. The pharmaceutical composition of any one of claims 1 to 10 further comprising a nonionic surfactant wherein the combined nonionic surfactant and sucrose fatty acid ester have a combined HLB of about 8 to about 17.

12. The pharmaceutical composition of claim 11 wherein the nonionic surfactant is at least one or more of polysorbate and sorbitan fatty acid ester.

13. The pharmaceutical composition of claim 12 wherein the polysorbate is selected from the group consisting of polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan and Polyoxyethylene (20) sorbitan monooleate.

14. The pharmaceutical composition of claim 12 or claim 13 wherein the sorbitan fatty acid ester is selected from the group consisting of sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate and sorbitan monooleate.

15. The pharmaceutical composition of any one of claims 1 to 14 further comprising a secondary absorption enhancer selected from the group consisting of glycerol, ginger oil, cineole and terpenes.

16. The pharmaceutical composition of any one of claims 1 to 15 further comprising a film forming agent selected from pullulan or a polymeric mixture of polyvinyl pyrrolidone and a polymeric alginate.

17. The pharmaceutical composition of claim 16 wherein the film forming agent is pullulan.

18. The pharmaceutical composition of claim 16 wherein the ratio of polyvinyl pyrrolidone to polymeric alginate in the polymeric mixture is from about 5:1 to about 1:3.

19. The pharmaceutical composition of claim 16 or claim 17 wherein the polymeric mixture contains, from about 5% to about 95% by weight of polyvinyl pyrrolidone and

from about 5% to about 95% by weight of an polymeric alginate, both of said weights being based on the weight of said polymeric mixture.

20. The pharmaceutical composition of any one of claims 1 to 19 wherein the matrix is a film.

21. The pharmaceutical composition of claim 20 further comprising a polymeric mixture of polyvinyl pyrrolidone and a polymeric alginate.

22. The pharmaceutical composition of claim 20 or claim 21 wherein the film when placed in the oral cavity will dissolve in about 0.25 minutes to about 15 minutes.

23. The pharmaceutical composition of any one of claims 20 to 22 wherein the film has a thickness of about 0.01 mm to about 5 mm.

24. The pharmaceutical composition of any one of claims 20 to 23 wherein said film has a surface area of from 0.25 cm^2 to 20 cm^2 and a weight of about 1 mg to about 200 mg.

25. The pharmaceutical composition of claim 24 wherein said film has a surface area of from 1 cm^2 to 10 cm^2 and a weight of about 10 mg to about 200 mg.

26. The pharmaceutical composition of any one of claims 20 to 25 wherein said film contains one or more absorption enhancers in an amount of from about 0.1% by weight to about 20% by weight of the film.

27. The pharmaceutical composition of claim 26 wherein said film contains a absorption enhancer in an amount of from about 1% by weight to about 10% by weight of the film.

28. The pharmaceutical composition of any one of claims 1 to 19 wherein the matrix is a tablet.

29. The pharmaceutical composition of claim 28 wherein the tablet when placed in the oral cavity will dissolve in about 0.25 minutes to about 15 minutes.

30. The pharmaceutical composition of any one of claims 28 to 29 wherein said tablet contains a absorption enhancer in an amount of from about 0.1% by weight to about 20% by weight of the tablet.

31. The pharmaceutical composition of any one of claims 1 to 19 wherein the matrix is a liquid.

32. The pharmaceutical composition of claim 31 wherein said liquid contains a absorption enhancer in an amount of from about 0.1% by weight to about 10% by weight of the liquid.

33. A method for treating prostate or breast cancer in a patient comprising administering an oral unit dosage form as a water soluble matrix to the oral mucosal membranes of the mouth of a patient, which matrix contains, dispersed therein, a pharmaceutical agent selected from the group consisting of diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol, said pharmaceutical agent being present in said matrix in an amount effective for treating said prostate or breast cancer, said matrix composed of one or more sucrose fatty acid esters having an HLB of about 8 to 16.

34. The method of claim 33 further comprising a polymeric mixture of polyvinyl pyrrolidone and a polymeric alginate.

35. The method of claim 34 wherein the ratio of polyvinyl pyrrolidone to polymeric alginate in the polymeric mixture is from about 5:1 to about 1:3.

36. The method of claim 34 wherein the polymeric mixture contains, from about 5% to about 95% by weight of polyvinyl pyrrolidone and from about 5% to about 95% by weight of an polymeric alginate, both of said weights being based on the weight of said polymeric mixture.

37. The method of any one of claims 33 to 36 wherein the diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol is present in an amount of about 0.1 to about 5 mg.

38. The method of any one of claims 33 to 37 wherein said matrix is placed under the tongue of said patient.

39. The method of any one of claims 33 to 37 wherein said matrix is inserted on the buccal tissue of the mouth of the patient.

40. The method of any one of claims 33 to 39 wherein the sucrose fatty acid ester has a monomer content of from about 20 percent to about 80 percent.

41. The method of any one of claims 33 to 40 wherein the sucrose fatty acid esters are selected from the group consisting of sucrose stearate, sucrose palmitate, sucrose laurate, sucrose behenate, sucrose oleate and sucrose erucate.

42. The method of any one of claims 33 to 41 wherein said sucrose fatty acid ester is present in an amount of from about 1% to about 20% based upon the weight of the film.

43. The method of any one of claims 33 to 42 further comprising a nonionic surfactant wherein the combined nonionic surfactant and sucrose fatty acid ester have a combined HLB of about 8 to about 17.

44. The method of any one of claims 33 to 43 further comprising a secondary absorption enhancer selected from the group consisting of glycerol, tween, span, ginger oil, cineole and terpenes.

45. The method of any one of claims 33 to 44 wherein the matrix is a film.

46. The method of any one of claims 33 to 44 wherein the matrix is a tablet.

47. The method of any one of claims 33 to 44 wherein the matrix is a liquid.

48. The method of any one of claims 33 to 47 further comprising pullulan as a film forming agent.

49. The method of any one of claims 33 to 48 wherein the active agent is released over a period of time from about 0.25 minutes to about 15 minutes.

50. The method of claim 49 wherein the active agent is released over a period of time from about 0.5 minutes to about 10 minutes.

51. Diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol for use in the treatment of prostate or breast cancer in a patient, comprising administering an oral unit dosage form as a water soluble matrix to the oral mucosal membranes of the mouth of a patient, which matrix contains, dispersed therein, diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol and wherein the diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol are present in said matrix in an amount effective for treating said prostate or breast cancer, said matrix composed of one or more sucrose fatty acid esters having an HLB of about 8 to 16.

52. The compound for use of claim 51, further comprising a polymeric mixture of polyvinyl pyrrolidone and a polymeric alginate.

53. The compound for use of claim 52 wherein the ratio of polyvinyl pyrrolidone to polymeric alginate in the polymeric mixture is from about 5:1 to about 1:3.

54. The compound for use, compound for use and use of claim 52 wherein the polymeric mixture contains, from about 5% to about 95% by weight of polyvinyl pyrrolidone and from about 5% to about 95% by weight of an polymeric alginate, both of said weights being based on the weight of said polymeric mixture.

55. The compound for use of any one of claims 51 to 54 wherein the diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol is present in an amount of about 0.1 to about 5 mg.

56. The compound for use of any one of claims 51 to 55 wherein said matrix is placed under the tongue of said patient.

57. The compound for use of any one of claims 51 to 55 wherein said matrix is inserted on the buccal tissue of the mouth of the patient.

58. The compound for use of any one of claims 51 to 57 wherein the sucrose fatty acid ester has a monomer content of from about 20 percent to about 80 percent.

59. The compound for use of any one of claims 51 to 58 wherein the sucrose fatty acid esters are selected from the group consisting of sucrose stearate, sucrose palmitate, sucrose laurate, sucrose behenate, sucrose oleate and sucrose erucate.

60. The compound for use of any one of claims 51 to 59 wherein said absorption enhancer is present in an amount of from about 1% to about 20% based upon the weight of the film.

61. The compound for use of any one of claims 51 to 60 further comprising a nonionic surfactant wherein the combined nonionic surfactant and sucrose fatty acid ester have a combined HLB of about 8 to about 17.

62. The compound for use of any one of claims 51 to 61 further comprising a secondary absorption enhancer selected from the group consisting of glycerol, tween, span, ginger oil, cineole and terpenes.

63. The compound for use of any one of claims 51 to 62 wherein the matrix is a film.

64. The compound for use of any one of claims 51 to 62 wherein the matrix is a tablet.

65. The compound for use of any one of claims 51 to 62 wherein the matrix is a liquid.

66. The compound for use of any one of claims 51 to 65 further comprising pullulan as a film forming agent.

67. The compound for use of any one of claims 51 to 66 wherein the active agent is released over a period of time from about 0.25 minutes to about 15 minutes.

68. The compound for use of claim 67 wherein the active agent is released over a period of time from about 0.5 minutes to about 10 minutes.

69. Use of diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol for the manufacture of a medicament for treatment of prostate or breast cancer in a patient, comprising administering an oral unit dosage form as a water soluble matrix to the oral mucosal membranes of the mouth of a patient, which matrix contains, dispersed therein, diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol and wherein the diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol are present in said matrix in an amount effective for treating said prostate or breast cancer, said matrix composed of one or more sucrose fatty acid esters having an HLB of about 8 to 16.

70. The use of claim 69 further comprising a polymeric mixture of polyvinyl pyrrolidone and a polymeric alginate.

71. The use of claim 70 wherein the ratio of polyvinyl pyrrolidone to polymeric alginate in the polymeric mixture is from about 5:1 to about 1:3.

72. The use of claim 70 wherein the polymeric mixture contains, from about 5% to about 95% by weight of polyvinyl pyrrolidone and from about 5% to about 95% by weight of an polymeric alginate, both of said weights being based on the weight of said polymeric mixture.

73. The use of any one of claims 69 to 72 wherein the diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol is present in an amount of about 0.1 to about 5 mg.

74. The use of any one of claims 69 to 73 wherein said matrix is placed under the tongue of said patient.

75. The use of any one of claims 69 to 73 wherein said matrix is inserted on the buccal tissue of the mouth of the patient.

76. The use of any one of claims 69 to 75 wherein the sucrose fatty acid ester has a monomer content of from about 20 percent to about 80 percent.

77. The use of any one of claims 69 to 76 wherein the sucrose fatty acid esters are selected from the group consisting of sucrose stearate, sucrose palmitate, sucrose laurate, sucrose behenate, sucrose oleate and sucrose erucate.

78. The use of any one of claims 69 to 77 wherein said absorption enhancer is present in an amount of from about 1% to about 20% based upon the weight of the film.

79. The use of any one of claims 69 to 78 further comprising a nonionic surfactant wherein the combined nonionic surfactant and sucrose fatty acid ester have a combined HLB of about 8 to about 17.

80. The use of any one of claims 69 to 79 further comprising a secondary absorption enhancer selected from the group consisting of glycerol, tween, span, ginger oil, cineole and terpenes.

81. The use of any one of claims 69 to 80 wherein the matrix is a film.

82. The use of any one of claims 69 to 80 wherein the matrix is a tablet.

83. The use of any one of claims 69 to 80 wherein the matrix is a liquid.

84. The use of any one of claims 69 to 83 further comprising pullulan as a film forming agent.

85. The use of any one of claims 69 to 84 wherein the active agent is released over a period of time from about 0.25 minutes to about 15 minutes.

86. The use of claim 85 wherein the active agent is released over a period of time from about 0.5 minutes to about 10 minutes.

What is claimed:

1. A pharmaceutical composition comprising:
a water soluble matrix comprising an effective amount of a pharmaceutically active agent and an absorption enhancer having an HLB of about 8 to about 16; wherein the pharmaceutically active agent is selected from the group consisting of diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol.

2. The pharmaceutical composition of claim 1 wherein the pharmaceutical composition dissolves in the oral cavity in about 0.25 minutes to about 15 minutes.

3. The pharmaceutical composition of claim 1 or claim 2 wherein the diethylstilbestrol is present in an amount of from about 0.1 mg to about 5 mg.

4. The pharmaceutical composition of any one of claims 1 to 3 wherein the pharmaceutical active agent is an agent for the treatment prostate or breast cancer in a patient and is present in an amount which is effective for treating prostate or breast cancer.

5. The pharmaceutical composition any one of claims 1 to 4 wherein said matrix contains an absorption enhancer or a combination of absorption enhancers in a total amount of from about 0.1% by weight to about 20% by weight by weight of the matrix.

6. The pharmaceutical composition of any one of claims 1 to 5 wherein the absorption enhancer is one or more sucrose fatty acid esters having a combined HLB of about 8 to about 16.

7. The pharmaceutical composition of claim 6 wherein the sucrose fatty acid esters are sucrose fatty acid esters having a monomer content of from about 20 percent to about 80 percent.

8. The pharmaceutical composition of claim 6 or claim 7 wherein said sucrose fatty acid ester is a C12 to C20 saturated fatty acid ester of sucrose.

9. The pharmaceutical composition of claim 6 or claim 7 wherein the sucrose fatty acid esters are selected from the group consisting of sucrose stearate, sucrose palmitate, sucrose laurate, sucrose behenate, sucrose oleate and sucrose erucate.

10. The pharmaceutical composition of any one of claims 6 to 9 wherein said sucrose fatty acid ester is a sucrose stearate.

11. The pharmaceutical composition of any one of claims 1 to 10 further comprising a nonionic surfactant wherein the combined nonionic surfactant and sucrose fatty acid ester have a combined HLB of about 8 to about 17.

12. The pharmaceutical composition of claim 11 wherein the nonionic surfactant is at least one or more of polysorbate and sorbitan fatty acid ester.

13. The pharmaceutical composition of claim 12 wherein the polysorbate is selected from the group consisting of polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan and Polyoxyethylene (20) sorbitan monooleate.

14. The pharmaceutical composition of claim 12 or claim 13 wherein the sorbitan fatty acid ester is selected from the group consisting of sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate and sorbitan monooleate.

15. The pharmaceutical composition of any one of claims 1 to 14 further comprising a secondary absorption enhancer selected from the group consisting of glycerol, ginger, oil, cineole and terpenes.

16. The pharmaceutical composition of any one of claims 1 to 15 further comprising a film forming agent selected from pullulan or a polymeric mixture of polyvinyl pyrrolidone and a polymeric alginate.

17. The pharmaceutical composition of claim 16 wherein the film forming agent is pullulan.

18. The pharmaceutical composition of claim 16 wherein the ratio of polyvinyl pyrrolidone to polymeric alginate in the polymeric mixture is from about 5:1 to about 1:3.

19. The pharmaceutical composition of claim 16 or claim 17 wherein the polymeric mixture contains, from about 5% to about 95% by weight of polyvinyl pyrrolidone and

from about 5% to about 95% by weight of an polymeric alginate, both of said weights being based on the weight of said polymeric mixture.

20. The pharmaceutical composition of any one of claims 1 to 19 wherein the matrix is a film.

21. The pharmaceutical composition of claim 20 further comprising a polymeric mixture of polyvinyl pyrrolidone and a polymeric alginate.

22. The pharmaceutical composition of claim 20 or claim 21 wherein the film when placed in the oral cavity will dissolve in about 0.25 minutes to about 15 minutes.

23. The pharmaceutical composition of any one of claims 20 to 22 wherein the film has a thickness of about 0.01 mm to about 5 mm.

24. The pharmaceutical composition of any one of claims 20 to 23 wherein said film has a surface area of from 0.25 cm^2 to 20 cm^2 and a weight of about 1 mg to about 200 mg.

25. The pharmaceutical composition of claim 24 wherein said film has a surface area of from 1 cm^2 to 10 cm^2 and a weight of about 10 mg to about 200 mg.

26. The pharmaceutical composition of any one of claims 20 to 25 wherein said film contains one or more absorption enhancers in an amount of from about 0.1 % by weight to about 20% by weight of the film.

27. The pharmaceutical composition of claim 26 wherein said film contains a absorption enhancer in an amount of from about 1 % by weight to about 10% by weight of the film.

28. The pharmaceutical composition of any one of claims 1 to 19 wherein the matrix is a tablet.

29. The pharmaceutical composition of claim 28 wherein the tablet when placed in the oral cavity will dissolve in about 0.25 minutes to about 15 minutes.

30. The pharmaceutical composition of any one of claims 28 to 29 wherein said tablet contains a absorption enhancer in an amount of from about 0.1% by weight to about 20% by weight of the tablet.

31. The pharmaceutical composition of any one of claims 1 to 19 wherein the matrix is a liquid.

32. The pharmaceutical composition of claim 31 wherein said liquid contains a absorption enhancer in an amount of from about 0.1% by weight to about 10% by weight of the liquid.

33. Diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol for use in the treatment of prostate or breast cancer in a patient, comprising administering an oral unit dosage form as a water soluble matrix to the oral mucosal membranes of the mouth of a patient, which matrix contains, dispersed therein, diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol and wherein the diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol are present in said matrix in an amount effective for treating said prostate or breast cancer, said matrix composed of one or more sucrose fatty acid esters having an HLB of about 8 to 16.

34. The compound for use of claim 33, further comprising a polymeric mixture of polyvinyl pyrrolidone and a polymeric alginate.

35. The compound for use of claim 34 wherein the ratio of polyvinyl pyrrolidone to polymeric alginate in the polymeric mixture is from about 5:1 to about 1:3.

36. The compound for use, compound for use and use of claim 34 wherein the polymeric mixture contains, from about 5% to about 95% by weight of polyvinyl pyrrolidone and from about 5% to about 95% by weight of an polymeric alginate, both of said weights being based on the weight of said polymeric mixture.

37. The compound for use of any one of claims 33 to 36 wherein the diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol is present in an amount of about 0.1 to about 5 mg.

38. The compound for use of any one of claims 33 to 37 wherein said matrix is placed under the tongue of said patient.

39. The compound for use of any one of claims 33 to 37 wherein said matrix is inserted on the buccal tissue of the mouth of the patient.

40. The compound for use of any one of claims 33 to 39 wherein the sucrose fatty acid ester has a monomer content of from about 20 percent to about 80 percent.

41. The compound for use of any one of claims 33 to 40 wherein the sucrose fatty acid esters are selected from the group consisting of sucrose stearate, sucrose palmitate, sucrose laurate, sucrose behenate, sucrose oleate and sucrose erucate.

42. The compound for use of any one of claims 33 to 41 wherein said absorption enhancer is present in an amount of from about 1% to about 20% based upon the weight of the film.

43. The compound for use of any one of claims 33 to 42 further comprising a nonionic surfactant wherein the combined nonionic surfactant and sucrose fatty acid ester have a combined HLB of about 8 to about 17.

44. The compound for use of any one of claims 33 to 43 further comprising a secondary absorption enhancer selected from the group consisting of glycerol, tween, span, ginger oil, cineole and terpenes.

45. The compound for use of any one of claims 33 to 44 wherein the matrix is a film.

46. The compound for use of any one of claims 33 to 45 wherein the matrix is a tablet.

47. The compound for use of any one of claims 33 to 35 wherein the matrix is a liquid.

48. The compound for use of any one of claims 33 to 47 further comprising pullulan as a film forming agent.

49. The compound for use of any one of claims 33 to 48 wherein the active agent is released over a period of time from about 0.25 minutes to about 15 minutes.

50. The compound for use of claim 49 wherein the active agent is released over a period of time from about 0.5 minutes to about 10 minutes.

51. Use of diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol for the manufacture of a medicament for treatment of prostate or breast cancer in a patient, comprising administering an oral unit dosage form as a water soluble matrix to the oral mucosal membranes of the mouth of a patient, which matrix contains, dispersed therein, diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol and wherein the diethylstilbestrol and pharmaceutically

acceptable salts of diethylstilbestrol are present in said matrix in an amount effective for treating said prostate or breast cancer, said matrix composed of one or more sucrose fatty acid esters having an HLB of about 8 to 16.

52. The use of claim 51 further comprising a polymeric mixture of polyvinyl pyrrolidone and a polymeric alginate.

53. The use of claim 52 wherein the ratio of polyvinyl pyrrolidone to polymeric alginate in the polymeric mixture is from about 5:1 to about 1:3.

54. The use of claim 52 wherein the polymeric mixture contains, from about 5% to about 95% by weight of polyvinyl pyrrolidone and from about 5% to about 95% by weight of an polymeric alginate, both of said weights being based on the weight of said polymeric mixture.

55. The use of any one of claims 51 to 54 wherein the diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol is present in an amount of about 0.1 to about 5 mg.

56. The use of any one of claims 51 to 55 wherein said matrix is placed under the tongue of said patient.

57. The use of any one of claims 51 to 55 wherein said matrix is inserted on the buccal tissue of the mouth of the patient.

58. The use of any one of claims 51 to 57 wherein the sucrose fatty acid ester has a monomer content of from about 20 percent to about 80 percent.

59. The use of any one of claims 51 to 58 wherein the sucrose fatty acid esters are selected from the group consisting of sucrose stearate, sucrose palmitate, sucrose laurate, sucrose behenate, sucrose oleate and sucrose erucate.

60. The use of any one of claims 51 to 59 wherein said absorption enhancer is present in an amount of from about 1% to about 20% based upon the weight of the film.

61. The use of any one of claims 51 to 60 further comprising a nonionic surfactant wherein the combined nonionic surfactant and sucrose fatty acid ester have a combined HLB of about 8 to about 17.

62. The use of any one of claims 51 to 61 further comprising a secondary absorption enhancer selected from the group consisting of glycerol, tween, span, ginger oil, cineole and terpenes.

63. The use of any one of claims 51 to 62 wherein the matrix is a film.

64. The use of any one of claims 51 to 62 wherein the matrix is a tablet.

65. The use of any one of claims 51 to 62 wherein the matrix is a liquid.

66. The use of any one of claims 51 to 65 further comprising pullulan as a film forming agent.

67. The use of any one of claims 51 to 66 wherein the active agent is released over a period of time from about 0.25 minutes to about 15 minutes.

68. The use of claim 67 wherein the active agent is released over a period of time from about 0.5 minutes to about 10 minutes.